LONDON/COPENHAGEN, June 23 (Reuters) - Shares in Novo Nordisk (NOVOb.CO), opens new tab fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled ...

Patients who took a lower dose lost more weight on average. Read more at straitstimes.com. Read more at straitstimes.com.

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

But as of today, Monday, June 23, GPs in England will be able to prescribe weight loss jabs for the first time on the NHS, as ...

Around 220,000 people with "greatest need" are expected to receive Mounjaro, also known as tirzepatide and made by Lilly ...

Over the next 12 years through NHS primary care providers, 1.6 million people are expected to receive tirzepatide, a weight ...

A major change in the rules starts on Monday and you must have four medical conditions as well as a specific BMI ...

The plastic pollution crisis has reached global levels, threatening planetary and human health, and recycling is proposed as ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Nearly 1 in 4 people have sarcopenic obesity, a dangerous condition mixing muscle loss and weight gain. Learn the warning signs and prevention tips.

Prescriptions for Mounjaro jabs, to help people lose weight, will be available at GP surgeries in England from today - but ...